Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Delaying disease progression by catheter ablation has been recognized in patients with paroxysmal atrial fibrillation (AF); however, its direct association with clinical outcome improvement remains unclear.
Objective: This study aimed to evaluate the effect of catheter ablation on reducing AF progression and associations with outcomes.
Methods: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial compared the efficacy of catheter ablation with drug therapy in 2204 patients with AF. CABANA participants with paroxysmal AF at enrollment were included in this subanalysis. The primary endpoint was time to the first documented episode of persistent AF after a 90-day blanking period.
Results: Among 2204 CABANA total population, 854 patients had paroxysmal AF at baseline, with 413 patients assigned to catheter ablation and 441 to drug therapy. During a median follow-up of 49.7 months, AF progression occurred in 66 patients (16.0%) of the ablation group compared with 122 patients (27.7%) of the drug treatment group (adjusted hazard ratio 0.52; 95% confidence interval 0.38-0.70). Among participants without AF progression, catheter ablation significantly reduced the incidence of death or cardiovascular hospitalization, whereas no significant effect was observed among those who developed AF progression. The mediation analysis identified that AF progression avoidance explained 23.3% of the treatment effect of catheter ablation compared with drug therapy in reducing death or cardiovascular hospitalization events.
Conclusion: In this post hoc analysis of the CABANA trial, catheter ablation significantly reduced the occurrence of AF progression. The large randomized trial data provide proof of concept evidence that progression avoidance by ablation may be transformed into clinical outcome improvements.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2025.07.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breaking the Circuit: A Case of Macro-re-entrant Biatrial Tachycardia.
J Innov Card Rhythm Manag
August 2025
Cardiology Division, Hamilton Health Sciences, Arrhythmia Service Unit, McMaster University, Hamilton, ON, Canada.
We present a case of a 71-year-old woman with symptomatic paroxysmal atrial fibrillation and atypical atrial flutter (AFL), ultimately diagnosed with a rare type 3 macro-re-entrant biatrial tachycardia (BiAT). Despite initial pulmonary vein isolation and anterior line ablation for atypical AFL, she experienced recurrent AFL requiring a complex redo ablation. Successful termination of the tachycardia was achieved by extending ablation to the septal regions of both atria.
View Article and Find Full Text PDFCase Report: From multimodality imaging to catheter ablation of ventricular arrhythmias in arrhythmogenic mitral valve prolapse.
Front Physiol
August 2025
Department of Electrophysiology, King Abdulaziz Cardiac Center, King Abdullah International Medical Research Center (KAIMRC), MNGHA, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Background: Mitral valve prolapse (MVP) is a common condition, typically benign, but in a small subset of patients, it may lead to life-threatening arrhythmias and sudden cardiac death (SCD). This arrhythmogenic MVP phenotype is often associated with bileaflet prolapse, mitral annular disjunction (MAD), and myocardial fibrosis identified via late gadolinium enhancement (LGE) on cardiac MRI.
Case Summary: Our patient is a 49-year-old man presented with monomorphic ventricular tachycardia and near-syncope.
Feasibility study of intravascular pulsed electric field ablation for the treatment of cardiac arrhythmias.
Front Physiol
August 2025
Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Background: Pulsed electric field ablation (PFA) techniques for treating cardiac arrhythmias have attracted considerable interest. For example, atrial fibrillation can be effectively treated by pulmonary vein isolation using PFA. However, some arrhythmias originate deep within the myocardium, making them difficult to reach with conventional ablation methods.
View Article and Find Full Text PDFOutcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmias.
Heart Rhythm O2
August 2025
Cardiac Electrophysiology Section, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Background: Cardiac amyloidosis (CA) is characterized by atrial myopathy, which predisposes patients to atrial fibrillation (AF) and other atrial arrhythmias (AA). Although catheter ablation of AA is effective in the general population, its efficacy and safety in patients with CA remain unclear.
Objective: The study aimed to evaluate outcomes in patients with CA undergoing catheter ablation for typical atrial flutter (TAFL) and left atrial (LA) arrhythmias and to assess the presence and influence of LA low-voltage areas (LVA) in the latter.
Dual-atria rotor modification: A comparative analysis of rotor modification and posterior wall isolation in patients with persistent and long-standing persistent atrial fibrillation.
Heart Rhythm O2
August 2025
Division of Cardiology, Tokyo Metropolitan Ohkubo Hospital, Shinjyuku-ku, Tokyo, Japan.
Background: Various methods have been devised for catheter ablation of persistent atrial fibrillation (AF). However, it remains difficult to understand the mechanism of AF and to determine the optimal method.
Objective: This study aimed to evaluate the effectiveness of rotor modification (RM) compared to posterior wall isolation (PWI) in the treatment of persistent AF.